Roles of the EZH2 histone methyltransferase in cancer epigenetics.

[1]  Gordon B Mills,et al.  Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers , 2008, Molecular carcinogenesis.

[2]  L. Wessels,et al.  Ubiquitin E3 Ligase Ring1b/Rnf2 of Polycomb Repressive Complex 1 Contributes to Stable Maintenance of Mouse Embryonic Stem Cells , 2008, PloS one.

[3]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[4]  O. Ohara,et al.  Polycomb group proteins Ring1A/B are functionally linked to the core transcriptional regulatory circuitry to maintain ES cell identity , 2008, Development.

[5]  Richard S. Jones,et al.  Recruitment of Drosophila Polycomb-group proteins by Polycomblike, a component of a novel protein complex in larvae , 2008, Development.

[6]  D. Reinberg,et al.  Ezh2 Requires PHF1 To Efficiently Catalyze H3 Lysine 27 Trimethylation In Vivo , 2008, Molecular and Cellular Biology.

[7]  S. Cross,et al.  The polycomb group protein EZH2 regulates actin polymerization in human prostate cancer cells , 2008, The Prostate.

[8]  Hengbin Wang,et al.  Role of hPHF1 in H3K27 Methylation and Hox Gene Silencing , 2007, Molecular and Cellular Biology.

[9]  J. Sklar,et al.  Effects of rearrangement and allelic exclusion of JJAZ1/SUZ12 on cell proliferation and survival , 2007, Proceedings of the National Academy of Sciences.

[10]  Haruhiko Koseki,et al.  Ring1-mediated ubiquitination of H2A restrains poised RNA polymerase II at bivalent genes in mouse ES cells , 2007, Nature Cell Biology.

[11]  Manolis Kellis,et al.  RNA polymerase stalling at developmental control genes in the Drosophila melanogaster embryo , 2007, Nature Genetics.

[12]  O. Hermanson,et al.  SMRT-mediated repression of an H3K27 demethylase in progression from neural stem cell to neuron , 2007, Nature.

[13]  D. Ghosh,et al.  A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. , 2007, Cancer research.

[14]  Michael F Clarke,et al.  The biology of cancer stem cells. , 2007, Annual review of cell and developmental biology.

[15]  J. Chai,et al.  Structural basis of EZH2 recognition by EED. , 2007, Structure.

[16]  I. Issaeva,et al.  UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development , 2007, Nature.

[17]  Carlos Caldas,et al.  Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis , 2007, Nature Reviews Cancer.

[18]  H. Stunnenberg,et al.  Pcl-PRC2 is needed to generate high levels of H3-K27 trimethylation at Polycomb target genes , 2007, The EMBO journal.

[19]  J Alfred Witjes,et al.  Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. , 2007, European urology.

[20]  J. Mchugh,et al.  Expression of polycomb group protein EZH2 in nevi and melanoma , 2007, Journal of cutaneous pathology.

[21]  R. Young,et al.  A Chromatin Landmark and Transcription Initiation at Most Promoters in Human Cells , 2007, Cell.

[22]  Howard Y. Chang,et al.  Functional Demarcation of Active and Silent Chromatin Domains in Human HOX Loci by Noncoding RNAs , 2007, Cell.

[23]  T. Jenuwein,et al.  Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. , 2007, Cancer cell.

[24]  Kelly M. McGarvey,et al.  DNA methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2. , 2007, Cancer research.

[25]  Jing Liang,et al.  Integration of Estrogen and Wnt Signaling Circuits by the Polycomb Group Protein EZH2 in Breast Cancer Cells , 2007, Molecular and Cellular Biology.

[26]  L. Wallrath,et al.  Connections between epigenetic gene silencing and human disease. , 2007, Mutation research.

[27]  U. Grossniklaus,et al.  Polycomb group and trithorax group proteins in Arabidopsis. , 2007, Biochimica et biophysica acta.

[28]  Xiaodong Cheng,et al.  Structural dynamics of protein lysine methylation and demethylation. , 2007, Mutation research.

[29]  Qiang Yu,et al.  Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. , 2007, Genes & development.

[30]  M. Fraga,et al.  The Polycomb group protein EZH2 directly controls DNA methylation , 2007, Nature.

[31]  F. Hamdy,et al.  EZH2 promotes proliferation and invasiveness of prostate cancer cells , 2007, The Prostate.

[32]  Kristian Helin,et al.  The Polycomb Group Protein Suz12 Is Required for Embryonic Stem Cell Differentiation , 2007, Molecular and Cellular Biology.

[33]  Karl Mechtler,et al.  Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. , 2007, Molecular cell.

[34]  Zohar Yakhini,et al.  Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer , 2007, Nature Genetics.

[35]  P. Laird,et al.  Epigenetic stem cell signature in cancer , 2007, Nature Genetics.

[36]  Kelly M. McGarvey,et al.  A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing , 2007, Nature Genetics.

[37]  Vincenzo Pirrotta,et al.  Polycomb silencing mechanisms and the management of genomic programmes , 2007, Nature Reviews Genetics.

[38]  Kelly M. McGarvey,et al.  The cancer epigenome--components and functional correlates. , 2006, Genes & development.

[39]  Anke Sparmann,et al.  Polycomb silencers control cell fate, development and cancer , 2006, Nature Reviews Cancer.

[40]  Jürg Müller,et al.  Polycomb response elements and targeting of Polycomb group proteins in Drosophila. , 2006, Current opinion in genetics & development.

[41]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[42]  R. Hoffman,et al.  Essential Role for Activation of the Polycomb Group (PcG) Protein Chromatin Silencing Pathway in Metastatic Prostate Cancer , 2006, Cell cycle.

[43]  Tapio Visakorpi,et al.  The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late‐stage prostate cancer , 2006, Genes, chromosomes & cancer.

[44]  Henriette O'Geen,et al.  Suz12 binds to silenced regions of the genome in a cell-type-specific manner. , 2006, Genome research.

[45]  M. Grever,et al.  Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. , 2006, Cancer research.

[46]  K. Yanagihara,et al.  Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer , 2006, Cancer science.

[47]  J. Zeitlinger,et al.  Polycomb complexes repress developmental regulators in murine embryonic stem cells , 2006, Nature.

[48]  Kristian Helin,et al.  Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. , 2006, Genes & development.

[49]  Megan F. Cole,et al.  Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells , 2006, Cell.

[50]  James A. Cuff,et al.  A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem Cells , 2006, Cell.

[51]  B. Steensel,et al.  Genome-wide profiling of PRC1 and PRC2 Polycomb chromatin binding in Drosophila melanogaster , 2006, Nature Genetics.

[52]  Michel Bellis,et al.  Chromosomal Distribution of PcG Proteins during Drosophila Development , 2006, PLoS biology.

[53]  S. Merajver,et al.  Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. , 2006, Cancer research.

[54]  Richard Bourgon,et al.  Genome-wide analysis of Polycomb targets in Drosophila melanogaster , 2006, Nature Genetics.

[55]  Cyrus Martin,et al.  Substrate Preferences of the EZH2 Histone Methyltransferase Complex* , 2006, Journal of Biological Chemistry.

[56]  M. Fraga,et al.  The Polycomb group protein EZH2 directly controls DNA methylation , 2006, Nature.

[57]  Johan Eide,et al.  Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  S. Baylin,et al.  Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? , 2006, Nature Reviews Cancer.

[59]  O. Halvorsen,et al.  EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Peter A. Jones,et al.  Epigenetic therapy of cancer: past, present and future , 2006, Nature Reviews Drug Discovery.

[61]  A. Feinberg,et al.  The epigenetic progenitor origin of human cancer , 2006, Nature Reviews Genetics.

[62]  Yi Zhang,et al.  Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. , 2005, Molecular cell.

[63]  Stephen A Boorjian,et al.  Increased Expression of the Polycomb Group Gene, EZH2, in Transitional Cell Carcinoma of the Bladder , 2005, Clinical Cancer Research.

[64]  Frank Lyko,et al.  DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. , 2005, Journal of the National Cancer Institute.

[65]  M. Hung,et al.  Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3 , 2005, Science.

[66]  N. Palavan-Unsal,et al.  Increased Expression of EZH2, a Polycomb Group Protein, in Bladder Carcinoma , 2005, Urologia Internationalis.

[67]  E. Heard.  Delving into the diversity of facultative heterochromatin: the epigenetics of the inactive X chromosome. , 2005, Current opinion in genetics & development.

[68]  Megan F. Cole,et al.  Core Transcriptional Regulatory Circuitry in Human Embryonic Stem Cells , 2005, Cell.

[69]  B. Ness,et al.  The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype , 2005, Oncogene.

[70]  S. Strome,et al.  Subunit Contributions to Histone Methyltransferase Activities of Fly and Worm Polycomb Group Complexes , 2005, Molecular and Cellular Biology.

[71]  Xing Zhang,et al.  The SET-domain protein superfamily: protein lysine methyltransferases , 2005, Genome Biology.

[72]  J. Köllermann,et al.  Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. , 2005, International journal of molecular medicine.

[73]  S. Horvath,et al.  Global histone modification patterns predict risk of prostate cancer recurrence , 2005, Nature.

[74]  K. Bhalla.  Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  Stormy J. Chamberlain,et al.  The Murine Polycomb Group Protein Eed Is Required for Global Histone H3 Lysine-27 Methylation , 2005, Current Biology.

[76]  Christoph Wülfing,et al.  Polycomb Group Protein Ezh2 Controls Actin Polymerization and Cell Signaling , 2005, Cell.

[77]  K. Mimori,et al.  Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[78]  T. Utsunomiya,et al.  Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma , 2005, British Journal of Cancer.

[79]  Maxim Nekrasov,et al.  Nucleosome binding and histone methyltransferase activity of Drosophila PRC2 , 2005, EMBO reports.

[80]  M. Fraga,et al.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.

[81]  D. Reinberg,et al.  Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[82]  C. Benz,et al.  Clinical development of histone deacetylase inhibitors as anticancer agents. , 2005, Annual review of pharmacology and toxicology.

[83]  G. Robertson,et al.  A novel human homologue of Drosophila polycomblike gene is up-regulated in multiple cancers. , 2004, Gene.

[84]  R. Kingston,et al.  Chromatin Compaction by a Polycomb Group Protein Complex , 2004, Science.

[85]  G. Lyons,et al.  The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. , 2004, Genes & development.

[86]  C. Meijer,et al.  Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. , 2004, Neoplasia.

[87]  Kristian Helin,et al.  Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity , 2004, The EMBO journal.

[88]  S. Strome,et al.  The MES-2/MES-3/MES-6 Complex and Regulation of Histone H3 Methylation in C. elegans , 2004, Current Biology.

[89]  Yi Zhang,et al.  SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. , 2004, Molecular cell.

[90]  D. Reinberg,et al.  Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. , 2004, Genes & development.

[91]  Yi Zhang,et al.  Hierarchical recruitment of polycomb group silencing complexes. , 2004, Molecular cell.

[92]  Peter A. Jones,et al.  Epigenetics in human disease and prospects for epigenetic therapy , 2004, Nature.

[93]  Paul Tempst,et al.  Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. , 2004, Molecular cell.

[94]  Yi Zhang,et al.  The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. , 2004, Current opinion in genetics & development.

[95]  Michael F. Clarke,et al.  Applying the principles of stem-cell biology to cancer , 2003, Nature Reviews Cancer.

[96]  P. V. van Diest,et al.  Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. , 2003, Neoplasia.

[97]  Kristian Helin,et al.  EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.

[98]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[99]  Andrew J. Bannister,et al.  Consequences of the depletion of zygotic and embryonic enhancer of zeste 2 during preimplantation mouse development , 2003, Development.

[100]  Youngchang Kim,et al.  Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP1 chromodomains. , 2003, Genes & development.

[101]  Arul M Chinnaiyan,et al.  Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. , 2003, Journal of the National Cancer Institute.

[102]  P. Laird.  Early detection: The power and the promise of DNA methylation markers , 2003, Nature Reviews Cancer.

[103]  B. Chait,et al.  Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement , 2003, Nature Immunology.

[104]  P. Farnham,et al.  Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. , 2003, Molecular cancer therapeutics.

[105]  D. Reinberg,et al.  Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. , 2002, Genes & development.

[106]  V. Pirrotta,et al.  Drosophila Enhancer of Zeste/ESC Complexes Have a Histone H3 Methyltransferase Activity that Marks Chromosomal Polycomb Sites , 2002, Cell.

[107]  Brigitte Wild,et al.  Histone Methyltransferase Activity of a Drosophila Polycomb Group Repressor Complex , 2002, Cell.

[108]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[109]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[110]  R. Kingston,et al.  The Core of the Polycomb Repressive Complex Is Compositionally and Functionally Conserved in Flies and Humans , 2002, Molecular and Cellular Biology.

[111]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[112]  Matty P. Weijenberg,et al.  A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer , 2002, Nature Genetics.

[113]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[114]  M. Surani,et al.  The Polycomb-Group GeneEzh2 Is Required for Early Mouse Development , 2001, Molecular and Cellular Biology.

[115]  C. Meijer,et al.  Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. , 2001, Blood.

[116]  M. Lohuizen,et al.  The Polycomb group--no longer an exclusive club? , 2001, Current opinion in genetics & development.

[117]  R. Willemze,et al.  The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma , 2001, British journal of haematology.

[118]  E. Jane,et al.  The Drosophila Polycomb Group proteins ESC and E(Z) are present in a complex containing the histone-binding protein p55 and the histone deacetylase RPD3. , 2001, Development.

[119]  C. Meijer,et al.  Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. , 2000, The American journal of pathology.

[120]  C. Ponting,et al.  Regulation of chromatin structure by site-specific histone H3 methyltransferases , 2000, Nature.

[121]  A. Otte,et al.  Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation , 1999, Nature Genetics.

[122]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[123]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.

[124]  C. Nislow,et al.  Mammalian homologues of the Polycomb‐group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S.cerevisiae telomeres , 1997, The EMBO journal.

[125]  A. Shearn,et al.  E(z): a polycomb group gene or a trithorax group gene? , 1996, Development.

[126]  O. Hobert,et al.  Isolation and developmental expression analysis of Enx-1, a novel mouse Polycomb group gene , 1996, Mechanisms of Development.

[127]  W. Gelbart,et al.  Genetic analysis of the enhancer of zeste locus and its role in gene regulation in Drosophila melanogaster. , 1990, Genetics.

[128]  G. Struhl,et al.  A gene product required for correct initiation of segmental determination in Drosophila , 1981, Nature.

[129]  E. Lewis.  A gene complex controlling segmentation in Drosophila , 1978, Nature.